The April 2026 final order by Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, citing treaty obligations and an HHS scientific review confirming accepted medical use. Broader rescheduling of all marijuana from Schedule I remains subject to the expedited DEA administrative hearing that concluded July 15, 2026, after which the agency filed a post-hearing brief arguing the substance no longer meets Schedule I criteria. The presiding administrative law judge has not yet issued a recommendation, and multiple challenges to the April order continue in the D.C. Circuit. Trader probabilities for full rescheduling by year-end stay low amid the pending ALJ decision, potential final rulemaking, and litigation timelines.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено$809,839 Обс.
Dec 31, 2026
September 30
2%
December 31
16%
$809,839 Обс.
September 30
$660 Обс.
2%
December 31
$199,608 Обс.
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 final order by Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, citing treaty obligations and an HHS scientific review confirming accepted medical use. Broader rescheduling of all marijuana from Schedule I remains subject to the expedited DEA administrative hearing that concluded July 15, 2026, after which the agency filed a post-hearing brief arguing the substance no longer meets Schedule I criteria. The presiding administrative law judge has not yet issued a recommendation, and multiple challenges to the April order continue in the D.C. Circuit. Trader probabilities for full rescheduling by year-end stay low amid the pending ALJ decision, potential final rulemaking, and litigation timelines.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Ринок відкрито: Feb 7, 2026, 5:04 PM ET
Обсяг
$809,839Дата завершення
Jan 1, 2027Ринок відкрито
Feb 7, 2026, 5:04 PM ETВирішувач
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 final order by Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, citing treaty obligations and an HHS scientific review confirming accepted medical use. Broader rescheduling of all marijuana from Schedule I remains subject to the expedited DEA administrative hearing that concluded July 15, 2026, after which the agency filed a post-hearing brief arguing the substance no longer meets Schedule I criteria. The presiding administrative law judge has not yet issued a recommendation, and multiple challenges to the April order continue in the D.C. Circuit. Trader probabilities for full rescheduling by year-end stay low amid the pending ALJ decision, potential final rulemaking, and litigation timelines.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Обсяг
$809,839Дата завершення
Jan 1, 2027Ринок відкрито
Feb 7, 2026, 5:04 PM ETВирішувач
0x65070BE91...The April 2026 final order by Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III under the Controlled Substances Act, citing treaty obligations and an HHS scientific review confirming accepted medical use. Broader rescheduling of all marijuana from Schedule I remains subject to the expedited DEA administrative hearing that concluded July 15, 2026, after which the agency filed a post-hearing brief arguing the substance no longer meets Schedule I criteria. The presiding administrative law judge has not yet issued a recommendation, and multiple challenges to the April order continue in the D.C. Circuit. Trader probabilities for full rescheduling by year-end stay low amid the pending ALJ decision, potential final rulemaking, and litigation timelines.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання